New Research Finds Rapamycin Extends Lifespan Similar to Caloric Restriction

For centuries, humans have pursued ways to prolong lifespan, often seeking mystical solutions like the philosopher's stone. Modern science, however, has shown that eating less—through dietary restriction—can significantly extend life, especially demonstrated in lab animals. The question now is whether we can replicate these benefits with drugs, making aging easier to manage without the discomfort or health risks associated with long-term dieting.

Recent studies highlight rapamycin, a drug initially discovered in bacteria from Easter Island soil and now used medically to prevent organ rejection, as a promising candidate. Rapamycin acts by inhibiting a cellular pathway involved in nutrient sensing and cell growth, effectively mimicking the anti-aging effects of dietary restriction. In contrast, another drug, metformin, commonly prescribed for type 2 diabetes and derived from a compound in French lilac, shows less consistent evidence in extending lifespan.

A comprehensive meta-analysis examined 167 studies across eight vertebrate species, from fish to primates, comparing the effects of eating less, rapamycin, and metformin on lifespan. Results confirmed that caloric restriction remains the most reliable method to prolong life, with rapamycin following closely behind. Interestingly, metformin did not demonstrate a clear longevity benefit across the studied species.

While these results are encouraging, translating them to humans requires caution. Most evidence stems from preclinical animal studies, and individual variations exist. Moreover, rapamycin is known to suppress the immune system and affect reproductive health, raising concerns about side effects. Researchers are exploring gentler dosing strategies to harness its benefits while minimizing risks.

Preliminary human trials are underway. For example, ongoing studies administering low, intermittent doses of rapamycin have shown positive indicators of healthspan, the period of life spent in good health. Similarly, trials with metformin aim to determine its potential in human longevity.

Though it is premature to prescribe rapamycin or any similar drugs for anti-aging purposes, these findings shed light on the possibility that targeting specific molecular pathways can mimic the benefits of calorie restriction. Continued research aims to develop therapies that promote healthier aging without compromising quality of life or taste preferences.